An interventional study of ST-1 and Miru 1day UpSide in Myopia, Soft Contact Lenses and Daily Disposable Soft Contact Lenses, sponsored by Menicon Co., Ltd.. Not yet recruiting at 6 sites in Taiwan. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-15.
Sponsored by Menicon Co., Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Myopia with a site in Taiwan — 6 open to participants now, 8 under way, none of them phase 3. Myopia · Taiwan.
Among the 40 studies in Myopia with a site in Taiwan, this one is the 17th largest by planned enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2026, is one of 23 with no phase, and was the 39th registered.
1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →6 of the 40 studies in Myopia with a site in Taiwan are open now. Recruiting first, the newest first:
Hungkuang University · Sites in Taiwan
Ages 15–22 · Healthy volunteers
Kubota Vision Inc. · Sites in Taiwan
Ages 6–13 · Healthy volunteers
Essilor-Polylite Taiwan Co., Ltd. · Sites in Taiwan
Ages 6–12 · Healthy volunteers
Buddhist Tzu Chi General Hospital · Sites in Taiwan
Ages 8–23
National Taiwan University Hospital · Sites in Taiwan
Ages 6–10
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 63 is below the median of 79 across 929 interventional studies indexed under Myopia.
Median enrollment 65 across the 31 interventional studies, 100 across the 9 observational. Of the 20 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 40 have an industry lead sponsor. The 10 most frequent:
Menicon Co., Ltd. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Menicon Co., Ltd. has 4 studies filed under Myopia — fewer than ten, so there is no comparison to draw.
3 of the studies in Myopia with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06579287Sunhawk Vision Biotech, Inc.A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control | 2026-12 |
| NCT07345416Menicon Co., Ltd.A Clinical Trial Assessing the Efficacy and Safety of ST-1 Silicone Hydrogel Daily Disposable Soft Contact Lenses Compared to Miru 1day UpSide | 2026-12-31 |
| NCT07107646National Taiwan University HospitalExploring Perceptual Learning in Blurred Gabor Discrimination for Low-Myopic Children | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 40 studies in Myopia with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will enroll 63 eligible subjects (126 eligible eyes, complete at least 108 evaluable eyes) in approximately 6 different medical centers in Taiwan, in order to evaluate the efficacy and safety of ST-1 silicone hydrogel daily disposable soft contact lenses (ST-1 lenses) compared to Miru 1day UpSide. Enrolled subjects will be randomized in a 2:1 test to control ratio at Visit 1. Each site will enroll 8 (intended minimum) to 12 (intended maximum) subjects. In order to eliminate the bias, the Investigators and the evaluators will be masked to the treatment assignment of the randomization code. During the study, the Investigator(s) will examine the ocular health via inquiry, slit lamp biomicroscopy (SLB), visual acuity (VA) test, keratometry, and refractive changes. The Investigator(s) will check ocular health and evaluate the inclusion/exclusion criteria of subjects at screening. After entering the study, subjects will be required to wear the lenses on a daily basis, record daily wearing time on a diary, return to the study site at scheduled visits for evaluations and complete the self-assessment questionnaire at Visit 2 to Visit 7 (1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Eyes with abnormality or disease as follows:
Subjects who wore monovision, multifocal, toric, or rigid contact lenses within 30 days prior to the Screening Visit.
Note: Monovision is defined as a vision correction method for treating presbyopia in which the dominant eye is corrected for distance vision and the non-dominant eye is corrected for near vision.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be randomized at Visit 1 with a 2:1 allocation ratio (approximately two-thirds assigned to this arm).
Device: ST-1
Subjects will be randomized at Visit 1 with a 2:1 allocation ratio (approximately one-third assigned to this arm).
Device: Miru 1day UpSide
ST-1 lens worn in daily wear, daily disposable mode.
Miru 1day UpSide lens worn in daily wear, daily disposable mode.
Corrected distance Logarithm of the Minimum Angle of Resolution (logMAR) visual acuity at the final visit (Visit 7)
Assessed using a Tumbling E Series ETDRS® chart.
Time frame: Screening, 3 months following enrolment
Self-assessment of eye symptoms
This questionnaire includes 11 items assessing symptoms during contact lens wear: discomfort, tearing, photophobia, itching, burning, halos, dryness, variable vision, blurred vision, pain, and other (specify if present). Scale: 0-4 (minimum = 0, maximum = 4), where higher scores indicate worse symptoms. Grades: 0 = None 1. = Trace 2. = Mild 3. = Moderate 4. = Severe
Time frame: Screening, 1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months following enrolment
Self-assessment of lens performance
This questionnaire includes 5 items assessing lens performance during contact lens wear: insertion comfort, overall comfort, vision, insertion handling, and removal handling. Scale: 0-5 (minimum = 0, maximum = 5), where higher scores indicate worse performance. Grades: 【comfort】 0 = Excellent 1 = Very comfortable 2 = Comfortable 3 = Slightly uncomfortable 4 = Very uncomfortable 5 = Causes pain 【vision】 0 = Excellent 1. = Very good 2. = Good 3. = Poor 4. = Very poor 5. = Unacceptable 【handling】 0 = Excellent 1. = Very good 2. = Good 3. = Poor 4. = Very poor 5. = Unmanageable
Time frame: Screening, 1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months following enrolment
Total wearing hours
Cumulative duration of lens wear throughout the study period, determined from the daily wearing time recorded by participants in the electronic patient-reported outcome (ePRO) diary.
Time frame: Daily for 3 months after enrollment
Total wearing days
Total number of days the study lenses were worn for 8 hours or more, based on the daily wearing time entered by participants in the electronic patient-reported outcome (ePRO) diary. A wearing day is defined as a day with 8 hours or more of lens wear.
Time frame: Daily for 3 months after enrollment
Average wearing hour each time
Average duration of lens wear for each individual application, derived from the wearing data entered by participants in the electronic patient-reported outcome (ePRO) diary.
Time frame: Daily for 3 months after enrollment
Daily wearing hour
Average number of hours the study lenses were worn per day, as recorded by participants in the electronic patient-reported outcome (ePRO) diary.
Time frame: Daily for 3 months after enrollment
Corrected distance visual acuity (CDVA) change with the dispensed lenses from baseline
Assessed using a Tumbling E Series ETDRS® chart.
Time frame: Screening, 1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months following enrolment
Slit lamp biomicroscopy (SLB) findings
Assessed using a slit lamp.
Time frame: Screening, 1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months following enrolment
Change from baseline in keratometry readings
To evaluate the absolute change from baseline in keratometry readings between Screening and the 3 months visit.
Time frame: Screening, 3 months following enrolment
Percent change from baseline in keratometry readings
To evaluate the percent change from baseline in keratometry readings between Screening and the 3-month visit.
Time frame: Screening, 3 months following enrolment
Change from baseline in refractive parameters
To evaluate the absolute change from baseline in refractive parameters, including sphere (S), cylinder (C), and axis (A), measured by subjective refraction test between Screening and the 3-month visit.
Time frame: Screening, 3 months following enrolment
Percent change from baseline in refractive parameters
To evaluate the percent change from baseline in refractive parameters, including sphere (S), cylinder (C), and axis (A), measured by subjective refraction test between Screening and the 3-month visit.
Time frame: Screening, 3 months following enrolment
Adverse events
AE will be evaluated by the investigator.
Time frame: Screening, 1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months following enrolment
Lens fitting and surface assessment
Lens fitting will be assessed with a slit lamp, and surface assessment will be assessed with a slit lamp or a stereomicroscope.
Time frame: 1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months following enrolment
Device deficiency
A device deficiency refers to any inadequacy of the investigational product regarding identity, quality, durability, reliability, safety, or performance, including malfunctions, use errors, and labeling issues. Categories include: Failure to meet product specifications (e.g., incorrect lens power/diameter/base curve/color) Lens cloudy or surface/edge defect Torn lens during handling/in pack Packaging deficit (e.g., mislabeled product, tampered seal, leaking container) Suspect contamination Lack of performance (e.g., fit changes under hypobaric or low-humidity conditions) Other If such an event occurs, investigators must evaluate, record, and report all deficiencies and malfunctions during the trial using the device deficiency evaluation form. The frequency of device deficiencies will be summarized for safety evaluation and compared between treatments.
Time frame: 1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months following enrolment
Overall lens dicontinuation rate
Permanent discontinuation of lens wear, if it occurs, will be recorded via ePRO. The overall discontinuation rate will be calculated and compared between treatments using Chi-square or Fisher's exact test.
Time frame: Daily for 3 months after enrollment
Lens discontinuation rate by reason
Reasons for permanent discontinuation (e.g., discomfort, adverse event, convenience), if they occur, will be collected via ePRO, categorized, and tabulated by visit and overall.
Time frame: Daily for 3 months after enrollment
Lens replacement
Lens replacement is defined as removal and reapplication of a lens, regardless of whether a new lens is used. If it occurs, all reasons (e.g., sleeping, rest, device deficiency, adverse events, other) will be recorded via ePRO and tabulated by visit and overall.
Time frame: Daily for 3 months after enrollment
Artificial tears usage frequency
Participants will record their daily usage of artificial tears via ePRO, if applicable. The record will include both the frequency of use and the number of drops applied each time.
Time frame: Daily for 3 months after enrollment
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Dec 2026, 7 months later.
Of 236 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's planned 7 months is above that.
Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Menicon Co., Ltd.